Merck’s Vytorin First Cholesterol Drug to Further Cut Heart Risk

November 17, 2014 1:59 PM

3 0

Merck & Co. (MRK:US)’s Vytorin reduced the risks of second heart attacks and strokes in patients already on aggressive therapy, making it the first medicine to improve on the current standard of care for lowering cholesterol.

The findings from the controversial 18,000-patient study, under way for almost a decade, met the study’s primary endpoint, Merck said today in a statement. The goal was to cut the rates of heart attack, stroke and death beyond the use of simvastatin, a powerful drug that has been a staple for 20 yea...

Also read: Louise Cooley, wife of famed heart surgeon, dead at 92

Read more

To category page